THAM acetate
Based on 1 publication(s) in Google Scholar
THAM acetate is a low-toxicity amino alcohol buffer, a CO2-consuming proton acceptor that buffers carbon dioxide and acid both in vitro and in vivo. THAM acetate binds protons to form bicarbonate, reduces PaCO2, and induces intracellular alkalization, thereby ameliorating hypercapnia-induced elevation of pulmonary blood vessels and pulmonary arterial pressure. THAM acetate may cause PaCO2 rebound, hypoglycemia, and respiratory depression. THAM acetate removes amniotic epithelium and preserves the basement membrane, but depletes extracellular matrix and reduces the adhesion rate of limbal epithelial cells. THAM acetate can act as a CO2 carrier to enhance the productivity and carbon utilization rate of Scenedesmus obliquus. THAM acetate is a key component of buffer solutions used in various biological, cell culture, biochemical, and molecular biology applications.
For research use only. We do not sell to patients.
- Purity: 97.0%
- CAS No.: 6850-28-8
- Formula: C6H15NO5
- Molecular Weight:181.19
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) THAM acetate
More
Biological Activity
THAM (5 min) induces intracellular alkalization in human HepG2 hepatocytes perfused with acidotic artificial media, with a larger effect in the presence of low extracellular non-bicarbonate buffer compared to high extracellular non-bicarbonate buffer[3].
THAM (110 μL) acetate induces intracellular alkalization in human HepG2 hepatocytes bathed in acidotic human blood[3].
THAM (2-8 mmol/L; 40 min) acetate enhances CO2 gas absorptivity and total inorganic carbon storage capacity of modified BG-11 medium, with the highest TIC absorption observed at 8 mmol·L-1[5].
THAM (2-8 mmol/L; 8 days) acetate improves biomass productivity of Scenedesmus dimorphus in indoor shake flask culture, while also increasing polyunsaturated fatty acid content and showing no biodegradation over 8 days[5].
THAM (6 mmol/L; 8 days) acetate increases biomass areal productivity of Scenedesmus dimorphus by 32-33% and CO2 utilisation efficiency by 6-12% in outdoor 2 m2 raceway pond culture, while also increasing polyunsaturated fatty acid content[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Piglets (23.0-30.5 kg body weight; acute respiratory distress syndrome induced by repeated lung lavages with 30 mL/kg 37-39 °C normal saline, eight total)[2]
-
Dosage:Calculated to normalize pH and provide lasting effect
-
Administration:i.v.; continuous infusion; 1 hour (6 animals); 3 hours (6 animals)
-
Result:Increased arterial pH above 7.4, decreased PaCO2, and increased base excess to 13.8 mEq/L (1-hour group) and 16.0 mEq/L (3-hour group) at 60 minutes.
Reduced pulmonary vascular resistance to 423 dyn·s/m5 (1-hour group) and 373 dyn·s/m5 (3-hour group) at 60 minutes, compared to 572 dyn·s/m5 in controls.
Rebounded PaCO2 to 15.2 kPa (1-hour group) and 22.6 kPa (3-hour group) at 6 hours post-infusion cessation.
Maintained elevated base excess at 10.2 mEq/L (1-hour group) and 27.8 mEq/L (3-hour group) at 6 hours post-infusion cessation.
Decreased pH to levels similar to controls by 6 hours post-infusion cessation.
Lowered pulmonary vascular resistance to 329 dyn·s/m5 (1-hour group) and 255 dyn·s/m5 (3-hour group) at 6 hours, compared to 450 dyn·s/m5 in controls.
Increased cardiac index to 5.0 L/min/m2 in the 3-hour group at 6 hours, compared to 3.5 L/min/m2 in controls.
Decreased arterial sodium concentration during infusion and increased arterial potassium concentration during infusion.
Showed no significant differences in lung mechanics (functional residual capacity, respiratory system compliance) between groups.
Increased lung tissue IL-6 concentration to 11.8 pg/mg protein in the 3-hour group, with no significant differences vs. controls for TNF-α or IL-1β.
Chemical Information
-
CAS No. 6850-28-8
-
Appearance Solid
-
Molecular Weight 181.19
-
Formula C6H15NO5
-
Color White to off-white
-
SMILES
OCC(CO)(N)CO.OC(C)=O
-
Synonyms
Tris acetate; Tris(hydroxymethyl)aminomethane acetate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
ACS Omega
Highly Efficient Photoelectrochemical Detection of Cystatin C Based on a Core-Shell MOF Nanocomposite with Biomimetic-Catalysis Amplification. [Abstract]2024 Jun 14;9(26):28228-28236. PMID: 38973831
Solvent & Solubility
DMSO : 100 mg/mL (551.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (301 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Nahas GG, et al. Guidelines for the treatment of acidaemia with THAM. Drugs. 1998;55(2):191-224. [Content Brief]
[2]. Höstman S, et al. THAM reduces CO2-associated increase in pulmonary vascular resistance - an experimental study in lung-injured piglets. Crit Care. 2015;19(1):331. Published 2015 Sep 17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.5191 mL | 27.5953 mL | 55.1907 mL | 137.9767 mL |
| 5 mM | 1.1038 mL | 5.5191 mL | 11.0381 mL | 27.5953 mL | |
| 10 mM | 0.5519 mL | 2.7595 mL | 5.5191 mL | 13.7977 mL | |
| 15 mM | 0.3679 mL | 1.8397 mL | 3.6794 mL | 9.1984 mL | |
| 20 mM | 0.2760 mL | 1.3798 mL | 2.7595 mL | 6.8988 mL | |
| 25 mM | 0.2208 mL | 1.1038 mL | 2.2076 mL | 5.5191 mL | |
| 30 mM | 0.1840 mL | 0.9198 mL | 1.8397 mL | 4.5992 mL | |
| 40 mM | 0.1380 mL | 0.6899 mL | 1.3798 mL | 3.4494 mL | |
| 50 mM | 0.1104 mL | 0.5519 mL | 1.1038 mL | 2.7595 mL | |
| 60 mM | 0.0920 mL | 0.4599 mL | 0.9198 mL | 2.2996 mL | |
| 80 mM | 0.0690 mL | 0.3449 mL | 0.6899 mL | 1.7247 mL | |
| 100 mM | 0.0552 mL | 0.2760 mL | 0.5519 mL | 1.3798 mL |